

October 28, 2024

The Honorable Monica De La Cruz
U.S. House of Representatives
1415 Longworth House Office Building
Washington, DC 20510

The Honorable Lou Correa
U.S. House of Representatives
2301 Rayburn House Office Building
Washington, DC 20510

Dear Representative De La Cruz and Representative Correa:

On behalf of the Endocrine Society, the world's largest professional organization of endocrinologists, we are pleased to endorse the Diabetes Prevention Program Reauthorization Act of 2024. Thank you for introducing this important legislation. Founded in 1916, the Endocrine Society represents approximately 18,000 physicians and scientists engaged in the treatment and research of endocrine disorders such as diabetes, hypertension, infertility, obesity, osteoporosis, endocrine tumors cancers (i.e., thyroid, adrenal, ovarian, pituitary), and thyroid disease. Our membership includes over 11,000 clinicians who are on the front lines in treating diabetes and obesity, two of the most common chronic illnesses in the United States.

This legislation would reauthorize the National Diabetes Prevention Program (National DPP) at the Centers for Disease Control and Prevention (CDC) for 5 years providing annual increases of \$5 million for the program. The National DPP is a highly successful program which offers evidence-based treatment for millions of Americans living with prediabetes and at increased risk of developing type 2 diabetes. According to the CDC, over 97 million American adults have prediabetes which represents approximately 38 percent of the population. The National DPP has shown tremendous success in delaying the onset of type 2 diabetes. The Program has [successfully demonstrated](#) that a 5-7 percent weight loss can reduce the risk of developing diabetes by 58 percent.

Diabetes prevention is a critical public health issue. Thank you for your leadership on this bipartisan legislation. The Endocrine Society is pleased to endorse the Diabetes Prevention Program Reauthorization Act of 2024, which will bring long-term stability to the National DPP. This bill will ensure that the National DPP continues to deliver highly effective interventions that improve public health for millions of Americans. We would be happy to work with you to pass this legislation.

If you have any questions or we can be of any further assistance, please contact Rob Goldsmith, Director of Advocacy and Policy at rgoldsmith@endocrine.org.



Sincerely,

A handwritten signature in black ink, appearing to read "Robert Lash".

Robert Lash, MD
Chief Medical Officer
Endocrine Society